$51.77
0.12% day before yesterday
Nasdaq, Dec 24, 07:01 pm CET

Supernus Pharmaceuticals, Inc. Stock price

$51.77
+6.62 14.66% 1M
+20.10 63.47% 6M
+15.61 43.17% YTD
+16.17 45.42% 1Y
+14.30 38.16% 3Y
+26.11 101.75% 5Y
+37.63 266.12% 10Y
+46.40 864.06% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.06 0.12%

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$2.7b
Net debt
positive
Cash
$281.2m
Shares outstanding
57.1m
Valuation (TTM | estimate)
P/E
negative | 18.3
P/S
4.4 | 4.1
EV/Sales
3.9 | 3.7
EV/FCF
38.0
P/B
2.8
Financial Health
Equity Ratio
75.7%
Return on Equity
7.1%
ROCE
3.8%
ROIC
3.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$681.5m | $716.9m
EBITDA
$124.6m | $130.3m
EBIT
$41.5m | $142.4m
Net Income
$-19.1m | $161.8m
Free Cash Flow
$70.8m
Growth (TTM | estimate)
Revenue
4.5% | 8.3%
EBITDA
-11.0% | -22.7%
EBIT
-30.0% | 57.2%
Net Income
-132.0% | 119.0%
Free Cash Flow
-58.9%
Margin (TTM | estimate)
Gross
89.9%
EBITDA
18.3% | 18.2%
EBIT
6.1%
Net
-2.8% | 22.6%
Free Cash Flow
10.4%
More
EPS
$-0.3
FCF per Share
$1.2
Short interest
12.3%
Employees
674
Rev per Employee
$980.0k
Show more

Is Supernus Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Supernus Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast:

Buy
83%
Hold
17%

Financial data from Supernus Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
682 682
5% 5%
100%
- Direct Costs 69 69
4% 4%
10%
613 613
6% 6%
90%
- Selling and Administrative Expenses 373 373
15% 15%
55%
- Research and Development Expense 107 107
3% 3%
16%
125 125
11% 11%
18%
- Depreciation and Amortization 83 83
3% 3%
12%
EBIT (Operating Income) EBIT 41 41
30% 30%
6%
Net Profit -19 -19
132% 132%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Supernus Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Supernus Pharmaceuticals, Inc. Stock News

Positive
The Motley Fool
10 days ago
Aristotle Capital Boston sold 503,122 shares of Supernus Pharmaceuticals in the third quarter. The move contributed to a net position change of about $10.9 million from the previous quarter.
Neutral
Seeking Alpha
17 days ago
Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Neutral
GlobeNewsWire
22 days ago
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual...
More Supernus Pharmaceuticals, Inc. News

Company Profile

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Head office United States
CEO Jack Khattar
Employees 674
Founded 2005
Website www.supernus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today